Sign in with your email address username.


[Comment] Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?

Are we ready to embrace the routine use of immune checkpoint inhibitors in patients with advanced stage non-small-cell lung cancer? In The Lancet, Roy Herbst and colleagues1 report the results of KEYNOTE-010, a randomised phase 2/3 study in 202 academic medical centres in 24 countries that compared two doses of pembrolizumab (2 mg/kg and 10 mg/kg) with docetaxel (75 mg/m2) every 3 weeks in 1034 patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. This biomarker-enriched study had two primary endpoints of overall survival and progression-free survival both in the total population and in the subgroup of patients with tumour proportion score of 50% or more, which is defined as the percentage of tumour cells expressing PD-L1 assessed by immunohistochemistry using antibody 22C3.